This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goggins, M. Search for Related Content PubMed PubMed Citation Articles by Goggins, M. Social Bookmarking                            What's this?

Molecular Markers of Early Pancreatic Cancer

Michael Goggins

From the Departments of Pathology, Medicine, and Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD

Address reprint requests to Michael Goggins, MD, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Department of Pathology, 720 Rutland Avenue, Baltimore, MD 21205-2196; e-mail: mgoggins{at}jhmi.edu.

Pancreatic cancer is a deadly disease and the fourth most common cause of cancer death in the United States. Since chemotherapy and radiotherapy have thus far largely failed to significantly improve the survival of patients with pancreatic ductal adenocarcinoma, there is considerable interest in identifying better diagnostic markers of pancreatic neoplasia. Not only could better markers improve the early diagnosis of pancreatic cancer and allow more patients to undergo curative surgical resection, but also could potentially be used for patients at high risk of developing pancreatic cancer to identify precancerous lesions while they are amenable to cure. A wealth of information has recently become available about gene expression, DNA methylation, and proteomics alterations that occur in pancreatic cancers creating hope that better diagnostic markers of pancreatic cancer will be soon forthcoming.

Author's disclosure of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. H.L. Tan, L. A. Birdsell, L. Martin, V. E. Baracos, and K. C.H. Fearon Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer Clin. Cancer Res., November 15, 2009; 15(22): 6973 - 6979. [Abstract] [Full Text] [PDF]

				M. J. Duffy, C. Sturgeon, R. Lamerz, C. Haglund, V. L. Holubec, R. Klapdor, A. Nicolini, O. Topolcan, and V. Heinemann Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report Ann. Onc., September 8, 2009; (2009) mdp332v2. [Abstract] [Full Text] [PDF]

				K. Walter, S.-M. Hong, S. Nyhan, M. Canto, N. Fedarko, A. Klein, M. Griffith, N. Omura, S. Medghalchi, F. Kuhajda, et al. Serum Fatty Acid Synthase as a Marker of Pancreatic Neoplasia Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2380 - 2385. [Abstract] [Full Text] [PDF]

				M. Gironella, M. Seux, M.-J. Xie, C. Cano, R. Tomasini, J. Gommeaux, S. Garcia, J. Nowak, M. L. Yeung, K.-T. Jeang, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development PNAS, October 9, 2007; 104(41): 16170 - 16175. [Abstract] [Full Text] [PDF]

				C. Melle, G. Ernst, N. Escher, D. Hartmann, B. Schimmel, A. Bleul, H. Thieme, R. Kaufmann, K. Felix, H. M. Friess, et al. Protein Profiling of Microdissected Pancreas Carcinoma and Identification of HSP27 as a Potential Serum Marker Clin. Chem., April 1, 2007; 53(4): 629 - 635. [Abstract] [Full Text] [PDF]

				A. Jimeno and M. Hidalgo Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796. [Abstract] [Full Text] [PDF]

				H. Matsubayashi, M. Canto, N. Sato, A. Klein, T. Abe, K. Yamashita, C. J. Yeo, A. Kalloo, R. Hruban, and M. Goggins DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease Cancer Res., January 15, 2006; 66(2): 1208 - 1217. [Abstract] [Full Text] [PDF]

				J. Koopmann, C. N. W. Rosenzweig, Z. Zhang, M. I. Canto, D. A. Brown, M. Hunter, C. Yeo, D. W. Chan, S. N. Breit, and M. Goggins Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 Clin. Cancer Res., January 15, 2006; 12(2): 442 - 446. [Abstract] [Full Text] [PDF]

				P. B. Fisher Is mda-7/IL-24 a "Magic Bullet" for Cancer? Cancer Res., November 15, 2005; 65(22): 10128 - 10138. [Abstract] [Full Text] [PDF]